On 22 Nov 2019, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) spotted trading -45.78% off 52-week high price. On the other end, the stock has been noted 54.77% away from the low price over the last 52-weeks. The stock changed 6.90% to recent value of $10.54. The stock transacted 1217144 shares during most recent day however it has an average volume of 880.41K shares. The company has 33.81M of outstanding shares and 33.4M shares were floated in the market.
AMAG Pharmaceuticals, Inc. (AMAG) recently stated unaudited consolidated financial results for the third quarter ended September 30, 2019 and provided a business update.
2019 FINANCIAL GUIDANCE UPDATE
“We’re tightening our guidance range for the full year of 2019. On a revenue basis, we are lowering the mid-point from $340M to $325M; however, we are lowering our predictable adjusted EBITDA loss from a mid-point of $80M to $70M by continuing to carefully manage expenses and aggressively re-prioritizing our spend to optimize the value in our portfolio,” stated Ted Myles, AMAG’s chief financial officer. “This is evident in our adjusted EBITDA loss trend, which was about $50M in the first half of 2019 and we expect to be less than $20M in the second half of 2019.”
Mr. Myles continued, “We firmly believe in Makena and are committed to working with the FDA. While these conversations continue, we recognize that the advisory committee vote heightens uncertainty about the durability of Makena revenue. We are prepared for a variety of potential scenarios and continue to look for ways to optimize the value of our portfolio to maximize shareholder value. As we gain more clarity on the path forward with the FDA regarding Makena, we’ll be in a better position to provide formal revenue and earnings guidance for 2020.”
THIRD QUARTER ENDED SEPTEMBER 30
The company’s commercial organization drove strong market share and revenue performance across all key marketed products.
- Makena SC auto-injector revenue totaled $41.3M, contrast with $39.2M in the same period last year, which is in-line with the company’s quarterly expectation for this product.
- The company did not ship any Makena IM product during the third quarter of 2019, therefore the full impact of the change in estimated commercial rebate liabilities from previous period sales appears as negative revenue during the quarter.
- Feraheme achieved record quarterly revenue of $44.2M, a raise of 20% over the same period last year. Feraheme’s average quarterly market share increased to 17.5%, contrast with 15.7% in the third quarter last year, and 17.2% in the second quarter of 2019.
- Intrarosa revenue in the third quarter of 2019 totaled $5.6M, contrast with $4.9M in the same period last year. The average quarterly share of total prescriptions grew to 4.8%, contrast with 3.8% in the third quarter last year, and 4.3% in the second quarter of 2019.
Its earnings per share (EPS) expected to touch remained 22.80% for this year. AMAG has a gross margin of 71.60% and an operating margin of -82.90% while its profit margin remained -88.50% for the last 12 months. According to the most recent quarter its current ratio was 1.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of 5.78% from the mean of 20 days, -4.57% from mean of 50 days SMA and performed -6.38% from mean of 200 days price. Company’s performance for the week was 6.90%, -11.20% for month and YTD performance remained -30.61%.